Published in Antiviral Res on January 01, 1997
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science (2008) 2.23
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog (2013) 2.16
Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep (2012) 1.84
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol (2004) 1.32
Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A (2013) 1.24
De novo assembly of Euphorbia fischeriana root transcriptome identifies prostratin pathway related genes. BMC Genomics (2011) 1.18
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog (2015) 1.18
HIV-1 latency in monocytes/macrophages. Viruses (2014) 1.13
Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol (2005) 1.05
Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs. Adv Virol (2012) 0.94
Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses (2015) 0.92
Variability in content of the anti-AIDS drug candidate prostratin in Samoan populations of Homalanthus nutans. J Nat Prod (2008) 0.89
CRISPR-mediated Activation of Latent HIV-1 Expression. Mol Ther (2015) 0.88
Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism. Sci Rep (2015) 0.85
The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication. EBioMedicine (2016) 0.79
Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells. J Immunol (2014) 0.78
Total synthesis of bryostatins: the development of methodology for the atom-economic and stereoselective synthesis of the ring C subunit. Chemistry (2011) 0.76
Prostratin exhibits both replication enhancing and inhibiting effects on FIV infection of feline CD4+ T-cells. Virus Res (2012) 0.76
Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV. J Virol (2016) 0.75
HMBA Enhances Prostratin-Induced Activation of Latent HIV-1 via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3 in NF-κB Signaling. Biomed Res Int (2016) 0.75
Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes. Tetrahedron Lett (2015) 0.75
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol (1998) 2.19
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science (1995) 2.16
Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother (1987) 2.11
Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. J Med Chem (1997) 2.08
Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res (1991) 2.06
Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) J Med Chem (1995) 1.98
Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res (1988) 1.95
Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A (1994) 1.94
The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem (1992) 1.89
A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem (1992) 1.80
Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol (1999) 1.57
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1986) 1.56
A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res (1991) 1.51
Cytotoxic geranyl stilbenes from Macaranga schweinfurthii. J Nat Prod (1998) 1.50
Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother (1989) 1.48
Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des (1995) 1.46
Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat liver epithelial cells in culture. Cancer Res (1986) 1.43
Evidence for the Clara cell as a site of cytochrome P450-dependent mixed-function oxidase activity in lung. Nature (1977) 1.41
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1993) 1.41
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res (1991) 1.37
Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem (1991) 1.32
Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol (2001) 1.31
Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 1.30
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res (1988) 1.29
Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther (2001) 1.28
Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod (1993) 1.26
Crystal structure of Escherichia coli HdeA. Nat Struct Biol (1998) 1.25
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A (1991) 1.24
Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol (2007) 1.23
Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem (1998) 1.23
A semiautomated multiparameter approach for anti-HIV drug screening. J Virol Methods (1991) 1.21
HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. J Nat Prod (1996) 1.19
HIV-inhibitory cembrane derivatives from a Philippines collection of the soft coral Lobophytum species. J Nat Prod (2000) 1.18
Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen. Am Rev Respir Dis (1979) 1.18
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother (1996) 1.17
Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects. Cancer Res (1984) 1.15
Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol (1988) 1.15
Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res (1995) 1.14
Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res (1988) 1.13
AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). J Natl Cancer Inst (1989) 1.12
T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 1.11
Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res (1993) 1.11
Thiazolinone analogues of indolmycin with antiviral and antibacterial activity. J Med Chem (1978) 1.10
Antineoplastic agents 430. Isolation and structure of cribrostatins 3, 4, and 5 from the republic of maldives cribrochalina species. J Nat Prod (2000) 1.10
A chemical screening strategy for the dereplication and prioritization of HIV-inhibitory aqueous natural products extracts. J Nat Prod (1993) 1.10
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res (1992) 1.10
Guttiferone F, the first prenylated benzophenone from Allanblackia stuhlmannii. J Nat Prod (1999) 1.09
Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. Mol Pharmacol (2000) 1.09
Purification and properties of a rat liver protein that specifically inhibits the proliferation of nonmalignant epithelial cells from rat liver. Proc Natl Acad Sci U S A (1982) 1.07
Role of TGF-beta in normal differentiation and oncogenesis in rat liver. Mol Carcinog (1989) 1.07
Siamenol, a new carbazole alkaloid from Murraya siamensis. J Nat Prod (2000) 1.07
Antineoplastic agents. 398. Isolation and structure elucidation of cephalostatins 18 and 19. J Nat Prod (1998) 1.06
Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors. J Med Chem (1996) 1.05
A pentahalogenated monoterpene from the red alga Portieria hornemannii produces a novel cytotoxicity profile against a diverse panel of human tumor cell lines. J Med Chem (1992) 1.05
Haligramides A and B, two new cytotoxic hexapeptides from the marine sponge Haliclona nigra. J Nat Prod (2000) 1.05
Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des (1998) 1.04
Studies directed towards the refinement of the pancratistatin cytotoxic pharmacophore. Bioorg Med Chem Lett (2001) 1.04
Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas. Cancer Res (1985) 1.03
Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res (1991) 1.03
Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob Agents Chemother (2000) 1.03
In vitro metabolic activation of the pulmonary toxin, 4-ipomeanol, in nonciliated bronchiolar epithelial (Clara) and alveolar type II cells isolated from rabbit lung. J Pharmacol Exp Ther (1982) 1.03
Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J Med Chem (1989) 1.03
Ethnobotany and drug discovery: the experience of the US National Cancer Institute. Ciba Found Symp (1994) 1.03
Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr Purif (1998) 1.02
Solution structure by NMR of circulin A: a macrocyclic knotted peptide having anti-HIV activity. J Mol Biol (1999) 1.02
Biochemical mechanisms in chemical-induced lung injury: roles of metabolic activation. Crit Rev Toxicol (1980) 1.02
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. J Med Chem (1999) 1.01
Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother (1993) 1.01